GW Pharmaceuticals Plc ADR (GWPH)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: PHARMACEUTICAL PREPARATIONS

SOVEREIGN HOUSE HISTON, CAMBRIDGE CB24 9BZ, UNITED KINGDOM

GW Pharmaceuticals plc, together with its subsidiaries, engages in the research, development, and commercialization of a range of cannabinoid prescription medicines. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in treatment of cancer pain.

Data based on most recent fiscal year report
Market Cap3.098 Billion Shares Outstanding27.77 Million Avg Volume537.156 Thousand
1-Yr BETA vs S&P TR1.175 Current Ratio7.59 Quick Ratio7.47
View SEC Filings from GWPH instead.
Q2 2019 All Institutions Hedge Funds 1
To trade GWPH now:
Filers who had this stock in their top 10: 4 2 (0.21%)
13F Filers holding this stock: 304 30 (3.1%)
Aggregate 13F shares on 06/30/2019: 25.507 Million 3.893 Million
Aggregate 13F shares on 03/31/2019: 23.799 Million 5.073 Million
Percent change: 7.18% -23.26%
Funds creating new positions: 52 5
Funds Adding to an existing position: 101 8
Funds closing out their position: 47 7
Funds reducing their position: 73 14
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GWPH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

12.3 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

3.6 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SNYDER DOUGLAS B. CHIEF LEGAL OFFICER

  • Officer
79,164 2019-08-12 5

MACKEY CATHERINE J

  • Director
0 2019-07-25 3

WALDEGRAVE WILLIAM A.

  • Director
0 2019-07-10 3

LYNCH THOMAS G

  • Director
212,500 2019-06-30 2

CLINE DARREN S

  • Director
35,468 2019-06-25 2

GOVER JUSTIN D. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
558,197 2019-06-14 9

TOVEY CHRISTOPHER J. CHIEF OPERATING OFFICER

  • Officer
2,503 2019-06-03 5

NOBLE JAMES

  • Director
27,500 2019-05-24 3

GIACOBELLO SCOTT M. CHIEF FINANCIAL OFFICER

  • Officer
87,096 2019-05-18 4

KNAPPERTZ VOLKER CHIEF MEDICAL OFFICER

  • Officer
85,824 2019-05-18 4

GANGOLLI JULIAN S PRESIDENT, NORTH AMERICA

  • Officer
106,548 2019-05-10 3

GEORGE ADAM D. SECRETARY

  • Officer
10,000 2019-05-07 4

SECOR ALICIA

  • Director
19,272 2019-03-13 4

BROWN CABOT

  • Director
3,636 2019-03-01 3

GUY GEOFFREY W DR EXECUTIVE CHAIRMAN

  • Officer
  • Director
8,245,446 2019-03-01 3

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

SNYDER DOUGLAS B. - Officer CHIEF LEGAL OFFICER

2019-08-12 S 3,756 $13.88 d 79,164 79,164.00 direct yes

WALDEGRAVE WILLIAM A. - Director

2019-07-10 S 3,576 $15.00 d 0 0.00 direct

WALDEGRAVE WILLIAM A. - Director

2019-07-10 M 3,576 $0.00 a 3,576 0.00 direct

WALDEGRAVE WILLIAM A. - Director

2019-07-10 M 3,576 d 7,164 0.00 direct

SNYDER DOUGLAS B. - Officer CHIEF LEGAL OFFICER

2019-07-09 S 4,968 $14.42 d 82,920 82,920.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments